JPMorgan Chase & Co. Increases Smith & Nephew (LON:SN) Price Target to GBX 1,381

Smith & Nephew (LON:SN) had its price objective upped by JPMorgan Chase & Co. from GBX 1,300 ($16.33) to GBX 1,381 ($17.35) in a note issued to investors on Thursday, Marketbeat reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 38.54% from the stock’s previous close.

Several other brokerages have also recently issued reports on SN. Royal Bank of Canada reaffirmed an “outperform” rating and set a GBX 1,500 ($18.84) target price on shares of Smith & Nephew in a research report on Friday, April 5th. Berenberg Bank reaffirmed a “buy” rating and set a GBX 1,450 ($18.21) target price on shares of Smith & Nephew in a research report on Thursday. Finally, Barclays reaffirmed an “equal weight” rating and issued a GBX 1,150 ($14.45) price objective on shares of Smith & Nephew in a research report on Friday, February 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Smith & Nephew presently has an average rating of “Moderate Buy” and an average price target of GBX 1,346.20 ($16.91).

Smith & Nephew Stock Up 1.1 %

LON:SN opened at GBX 996.80 ($12.52) on Thursday. The company has a debt-to-equity ratio of 59.11, a current ratio of 1.77 and a quick ratio of 0.84. Smith & Nephew has a 1-year low of GBX 887 ($11.14) and a 1-year high of GBX 1,316.75 ($16.54). The company has a 50-day moving average of GBX 1,021.40 and a 200 day moving average of GBX 1,034.26. The firm has a market cap of £8.72 billion, a PE ratio of 4,106.67, a price-to-earnings-growth ratio of 0.46 and a beta of 0.51.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.